Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Edgewise Therapeutics, Inc. (EWTX : NSDQ)

• Company Description    Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States. Number of Employees: 146

• Price / Volume Information    Yesterday's Closing Price: $32.70 Daily Weekly Monthly 20 Day Moving Average: 1,400,465 shares Shares Outstanding: 107.59 (millions) Market Capitalization: $3,518.29 (millions) Beta: 0.25 52 Week High: $39.94 52 Week Low: $12.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.71% -0.41% 12 Week 10.25% 1.92% Year To Date 31.78% 21.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1715 38TH ST - BOULDER,CO 80301 USA ph: 720-262-7002 fax: - ir@edgewisetx.com http://www.edgewisetx.com

• General Corporate Information    Officers Kevin Koch - President; Chief Executive Officer and Director Peter Thompson - Chairman and Director Michael Nofi - Chief Financial Officer Alan Russell - Chief Scientific Officer and Director Laura A. Brege - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28036F105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 107.59 Most Recent Split Date: (:1) Beta: 0.25 Market Capitalization: $3,518.29 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.51 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.13 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.13 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -6.98% vs. Previous Quarter: 2.13% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -32.55 12/31/25 - -31.97 09/30/25 - -30.88 ROA 03/31/26 - -31.04 12/31/25 - -30.46 09/30/25 - -29.42 Current Ratio 03/31/26 - 22.61 12/31/25 - 19.85 09/30/25 - 26.51 Quick Ratio 03/31/26 - 22.61 12/31/25 - 19.85 09/30/25 - 26.51 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 4.58 12/31/25 - 4.93 09/30/25 - 5.30 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©